Efti’s targeting activation of antigen-presenting cells delivers an adaptive immunity to fight cancer

The Oxford-based biotech company has secured £13.2m to progress world’s vital treatment development

Product delivers epigenetic information from a single low-input DNA library without medical treatment

Notable first clearance for R21/Matrix-M malaria vaccine for use in a specific country

Decision will create opportunity for therapy to be used earlier in the treatment pathway

Partnership will develop technology to screen and diagnose Lyme disease and diabetes

The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab

Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation

Treatment concerns adults and adolescents with stage IIB or IIC melanoma skin cancer

Updated Date: Mon, 03 Apr 2023 00:00:00 EDT